Longeveron walks into its May 13 earnings report carrying a fresh clinical setback and a downgrade — yet the short side has quietly retreated from its worst levels of the past month.
The most significant development is not in the positioning data but in the pipeline. On May 8, the FDA told Longeveron that its ELPIS II Phase 2b trial of Lomecel-B in Hypoplastic Left Heart Syndrome will no longer be considered pivotal — meaning a positive readout alone will not be sufficient to support a direct approval pathway. That reclassification landed on the same day as the most recent earnings event and triggered an immediate 1.6% decline. Then, on May 11, the company's independent data monitoring committee cleared the trial to continue as designed, with top-line results now expected in August 2026. The stock closed at $0.84 Monday, down 28% over the past month and nearly halved from its range earlier in the year.
The short side tells a nuanced story. Short interest has pulled back materially from its April peak — shares short fell from roughly 3.6 million in early April to around 2.0 million now, bringing the SI % of FF to 10.2%. That decline in bearish conviction is notable. Yet borrowing costs, though easing fast, remain elevated at nearly 42% annualised — down from a peak near 120% in late March but still high enough to deter casual positioning. The ORTEX short score sits at 73.5, placing this stock in a high-conviction short territory by percentile rank. Availability has tightened from its 52-week extremes, suggesting the remaining borrow pool is not abundant.
Analyst opinion split sharply this week. Maxim Group downgraded to Hold on May 11, removing the last active Buy from a firm that had held the rating through successive target cuts. HC Wainwright maintained its Buy rating just days earlier but cut its target from $10 to $8 — itself a concession that the stock's near-term path has narrowed. With the stock at $0.84 and even the most optimistic targets implying a multi-bagger, the gap between the bull case and the current price reflects how binary the clinical read-out has become. Bulls point to the 100% five-year transplant-free survival rate in earlier HLHS data and the DMC's green light as proof the science still holds. Bears focus on the FDA's decision to strip the trial of its pivotal designation, the ongoing dilution risk, and the stock's sustained underperformance.
The May 13 print is therefore less a financial event and more a clinical narrative checkpoint — the earnings release will test whether management can articulate a credible bridge to the August top-line read-out, and whether investors see enough in the DMC clearance to hold conviction through the wait.
See the live data behind this article on ORTEX.
Open LGVN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
